AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|AAPL338.32-6.31 (-1.83%) ▼|ABBV288.84-6.05 (-2.05%) ▼|ABT110.16+3.96 (+3.73%) ▲|ACN260.94+2.70 (+1.05%) ▲|ADBE251.47+1.24 (+0.50%) ▲|AMAT374.53-15.56 (-3.99%) ▼|AMD466.84-37.96 (-7.52%) ▼|AMGN465.45-0.56 (-0.12%) ▼|AMT188.30+0.52 (+0.28%) ▲|AMZN245.63+5.28 (+2.20%) ▲|AVGO322.23-3.85 (-1.18%) ▼|AXP327.98+8.87 (+2.78%) ▲|BA175.40+3.85 (+2.24%) ▲|BAC49.57-0.44 (-0.88%) ▼|BKNG153.75+5.62 (+3.79%) ▲|BLK1,167.15+19.61 (+1.71%) ▲|BMY63.02+0.54 (+0.86%) ▲|BNY147.78+0.67 (+0.46%) ▲|BRK-B556.11+13.62 (+2.51%) ▲|C123.10+1.13 (+0.93%) ▲|CAT613.62-9.13 (-1.47%) ▼|CL97.43+2.14 (+2.25%) ▲|CMCSA23.87+0.65 (+2.80%) ▲|COF210.77+5.92 (+2.89%) ▲|COP146.84-7.19 (-4.67%) ▼|COST1,040.55+28.27 (+2.79%) ▲|CRM226.18-2.99 (-1.30%) ▼|CSCO101.61-2.90 (-2.77%) ▼|CVS88.51-1.74 (-1.93%) ▼|CVX227.77-7.75 (-3.29%) ▼|DE667.60-7.88 (-1.17%) ▼|DHR227.97-4.26 (-1.83%) ▼|DIS113.11+2.17 (+1.96%) ▲|DUK128.38+0.99 (+0.78%) ▲|EMR165.96+1.02 (+0.62%) ▲|FDX318.25+4.97 (+1.59%) ▲|GD373.46+0.87 (+0.23%) ▲|GE315.78+13.98 (+4.63%) ▲|GEV862.25+4.38 (+0.51%) ▲|GILD170.33-0.35 (-0.21%) ▼|GM89.94+2.54 (+2.91%) ▲|GOOG278.04-0.18 (-0.06%) ▼|GOOGL278.99-0.85 (-0.30%) ▼|GS898.72+4.17 (+0.47%) ▲|HD341.15+11.95 (+3.63%) ▲|HON223.77+5.44 (+2.49%) ▲|IBM252.51-5.30 (-2.06%) ▼|INTC59.97-5.79 (-8.80%) ▼|INTU352.10+11.01 (+3.23%) ▲|ISRG436.87+4.86 (+1.13%) ▲|JNJ270.56-2.64 (-0.97%) ▼|JPM340.58+3.54 (+1.05%) ▲|KO95.83+1.75 (+1.86%) ▲|LIN519.72+5.48 (+1.07%) ▲|LLY1,410.99-6.55 (-0.46%) ▼|LMT643.15+6.20 (+0.97%) ▲|LOW218.15+9.08 (+4.34%) ▲|LRCX227.56-11.55 (-4.83%) ▼|MA658.10+20.09 (+3.15%) ▲|MCD265.64+7.52 (+2.91%) ▲|MDLZ66.38+1.44 (+2.22%) ▲|MDT99.29+2.75 (+2.85%) ▲|META606.73-8.26 (-1.34%) ▼|MMM178.36+4.02 (+2.31%) ▲|MO77.17-0.86 (-1.10%) ▼|MRK148.36-1.16 (-0.78%) ▼|MS185.73+1.43 (+0.78%) ▲|MSFT507.12-14.79 (-2.83%) ▼|MU833.59-51.15 (-5.78%) ▼|NEE85.03+1.32 (+1.58%) ▲|NFLX62.34+0.26 (+0.42%) ▲|NKE39.12+0.45 (+1.16%) ▲|NOW106.01+0.89 (+0.85%) ▲|NVDA202.06-2.58 (-1.26%) ▼|ORCL119.22-11.45 (-8.76%) ▼|PEP140.42+3.08 (+2.24%) ▲|PFE30.67+0.15 (+0.49%) ▲|PG163.56+1.99 (+1.23%) ▲|PLTR178.34-5.77 (-3.13%) ▼|PM208.29-0.50 (-0.24%) ▼|QCOM162.08-2.71 (-1.64%) ▼|RTX202.79+2.99 (+1.50%) ▲|SBUX104.40+0.75 (+0.72%) ▲|SCHW88.71+0.66 (+0.75%) ▲|SO94.61+0.90 (+0.96%) ▲|SPG221.73+3.98 (+1.83%) ▲|T21.44+0.03 (+0.14%) ▲|TMO682.65-14.35 (-2.06%) ▼|TMUS160.15+3.71 (+2.37%) ▲|TSLA403.82+4.01 (+1.00%) ▲|TXN302.02+1.18 (+0.39%) ▲|UBER66.71+1.46 (+2.24%) ▲|UNH400.44-6.53 (-1.60%) ▼|UNP307.00+3.00 (+0.99%) ▲|UPS109.71+1.46 (+1.35%) ▲|USB60.49+1.04 (+1.75%) ▲|V425.51+11.92 (+2.88%) ▲|VZ45.05+0.32 (+0.72%) ▲|WFC85.89+2.49 (+2.99%) ▲|WMT127.69+4.18 (+3.38%) ▲|XOM179.67-7.58 (-4.05%) ▼|
15.2 C
New York
Tuesday, November 3, 2026

Tag: health

newsFORsourcecompanycontentinformationreleases1market

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Clinical Amino Acid Profiles Anchor PureHealth Research’s New Natural Peptides Supplements

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today pointed to the growing scientific interest in naturally sourced peptide nutrition for healthy aging...

PureHealth Research Highlights Growing Consumer Interest in Lymphatic Wellness and Botanical Support

MANASSAS, Va., June 6, 2026 /PRNewswire/ -- PureHealth Research today highlighted the growing consumer interest in lymphatic wellness and the role botanicals may play...

SKG Launches PS700 Neck Massager, Bringing Deep Kneading, Layered Heat, and Immersive Audio to Everyday Recovery

The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension 
The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension

Horse Boost For Men Claims Evaluated: Documenting Horse Boost Male Enhancement: A New Male Wellness Supplement Amid Growing Interest in Men’s Health Solutions

Horse Boost for Men supports male vitality, energy, stamina, endurance, and active lifestyles with targeted nutritional support. 
Horse Boost for Men supports male vitality, energy, stamina, endurance, and active lifestyles with targeted nutritional support.

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may...

Leading Vision Insurance for Glasses (2026): VSP Individual Vision Plans Named Top Plan for Frames and Lens Coverage by Better Business Advice

NEW YORK, June 6, 2026 /PRNewswire/ -- VSP® Individual Vision Plans has been recognized by Better Business Advice as a top vision insurance option...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealth

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers